Table 3 Summary of the main data from the studies included
Study | Chronic disease | Number of participants | Control group | Timeline (weeks) | Mean age (years) | Sex M/F | Program’s goal | PA outcome | Adherence | Primary outcome of each study | Secondary outcomes of each study |
|---|---|---|---|---|---|---|---|---|---|---|---|
Backman et al. [51] | Breast and colorectal cancer | 39 | Yes | 10 | 54 | 8/31 | 10,000 steps | Step counts | ≃ 90% week 1, ≃ 85% week 10a | Adherence to PA intervention | HRQoL, body composition and blood markers |
Benzo et al. [52] | COPD | 12 | No | 8 | > 40 | Not specified | 12 min walk | Walking minutes | 89 ± 0.22% | Program feasibility | WAI-SR |
Gary et al. [53] | HF | 24 | Yes | 12 | 60 | 12/12 | Individualized: from 30 to 60 walking minutes, 3 times per week | Walking minutes, daily steps | 83% | CS-PFP10 | Muscle strength, HRQoL, functional capacity, disease severity levels |
COPD | 10 | No | 156 | 55 | 5/5 | Individualized | Training sessions | 69.1% year 1, 40.5% year 2, 13.9% year 3 (9/10)b | Adherence | System Usability Scale | |
Mendoza et al. [49] | COPD | 50 | Yes | 13 | 68 | 33/17 | Personalized | Step counts | 80±31% week 4, 85 ± 26% week 8, 81 ± 22% week 13c | Daily step counts | Exercise capacity (6MWT), health status (SGRQ, CAT) |
Moy et al. [54] | COPD | 27 | No | 13 | 72 | 27/0 | Personalized | Step counts | 90.39% at baseline, 104.82% week 12a | Daily step counts | General health status, MMRC dyspnea score, Bristol knowledge, exercise self-efficacy |
Pinto et al. [55] | Breast cancer survivors | 43 | Yes (but not analyzed) | 12 | 53 | 0/43 | Personalized | Exercise minutes, step counts | 88.37% week 1, 55.81% week 12 | Adherence | Exercise self-efficacy |